Menu
Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2
Rituximab in severe skin diseases: target, disease, and dose
Authors Bennett DD, Ohanian M, Cable C
Published 7 July 2010 Volume 2010:2 Pages 135—141
DOI https://doi.org/10.2147/CPAA.S10929
Review by Single anonymous peer review
Peer reviewer comments 1
Daniel D Bennett1, Maro Ohanian2, Christian T Cable2
1Department of Dermatology, 2Department of Internal Medicine, Division of Hematology and Oncology, Scott and White Healthcare, Texas A&M Health Science Center College of Medicine. Temple, TX, USA
Abstract: New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy (atrophie blanche) responding to rituximab will illustrate how the response to therapy can help to elucidate previously obscure pathophysiology.
Keywords: rituximab, livedoid vasculopathy, pharmacokinetics, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.